Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

DISEASE CHARACTERISTICS: Histologically confirmed renal cell carcinoma (RCC) Histology demonstrates major clear cell component Metastatic (stage IV) or recurrent disease Prior debulking nephrectomy required Disease not amenable to complete surgical resection Must have HLA-identical donor Matched related sibling donors must have 6/6 serologic HLA A, B, and DR match with molecular confirmation at DRB1 A 5/6 serologic mismatch with one antigen mismatch at locus A or B (not DR) with molecular confirmation at locus A, B, and DRB1 allowed Matched unrelated donors must have a minimum of 8 out of 10 molecular matches at loci A, B, C, DRB1, and DQB1 No brain metastases Negative MRI required PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: Karnofsky 80-100% OR ECOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) ALT/AST less than 2 times ULN Alkaline phosphatase less than 2 times ULN Hepatitis A, B, and C negative Renal: Creatinine clearance greater than 50 mL/min Calcium less than 10.5 mg/dL (bisphosphonates allowed) Cardiovascular: LVEF no less than 10% below lower limit of normal Pulmonary: FEV_1 and DLCO greater than 50% Other: HIV negative No active bacterial, fungal, or viral (including cytomegalovirus) infections No intolerance or allergy to tacrolimus, mycophenolate mofetil, or fludarabine No intolerance to 200 cGy of total body irradiation No other serious comorbid disease, neurologic condition, or psychosocial condition that would preclude study follow-up Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception for at least 1 month before, during, and for at least 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy: Prior interleukin-2 allowed Prior interferon alfa allowed Chemotherapy: Prior chemotherapy allowed No other concurrent chemotherapy for RCC Endocrine therapy: No concurrent corticosteroids for other comorbid disease Radiotherapy: No prior extensive radiotherapy to marrow microenvironment greater than 20% of total marrow mass No prior radiotherapy that has reached tissue tolerance for heart, lung, liver, kidney, or spinal cord Surgery: See Disease Characteristics Other: No other concurrent therapy for RCC No concurrent enrollment on another investigational protocol for treatment of RCC No other concurrent immunosuppressive medications No other concurrent investigational drugs